美国门诊心血管诊疗中射血分数降低的心力衰竭患者使用SGLT2抑制剂的情况
老年、女性及收缩压较高者使用率较低,且不同诊疗机构间存在显著差异。
要点
- SGLT2i使用率在研究期间从4.6%升至16.2%,但总体仍仅10.1%。
- HFrEF患者使用率从5.1%升至28.5%,HFmrEF/HFpEF从4.5%升至12.8%。
- 老年、女性及较高收缩压与SGLT2i使用率较低相关,而2型糖尿病病史与使用率显著升高相关。
核心结论
- 尽管门诊心衰患者中SGLT2i使用率有所增加,但大多数符合条件的患者未接受该治疗。
- 老年、女性及较高血压与较低使用率相关,且不同诊疗机构间存在显著无法解释的差异。
研究设计与样本
- 平均年龄70岁(标准差14),女性占47.3%,黑人占14.6%,白人占82.7%。
主要发现
- 全体患者SGLT2i使用率从2019年第三季度的4.6%升至2023年第二季度的16.2%(趋势P<.001)。
- HFrEF患者使用率从5.1%升至28.5%,HFmrEF或HFpEF从4.5%升至12.8%(趋势P<.001)。
- 老年(OR 0.76;95%CI 0.75-0.77)、女性(OR 0.79;95%CI 0.77-0.81)及较高收缩压(OR 0.78;95%CI 0.77-0.79)与较低使用率相关;2型糖尿病病史与更高使用率相关(OR 3.21;95%CI 3.15-3.28)。
临床怎么用
- 应系统性地提高心衰患者中SGLT2i的使用率,尤其是老年、女性及血压较高者。
- 需关注不同诊疗机构间的使用差异,并采取针对性改进措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy reduces risk of heart failure (HF) events and cardiovascular death among individuals with HF. Trends of SGLT2i use in cardiovascular ambulatory care in the US remain unknown. OBJECTIVE: To evaluate the rate of SGLT2i use among patients with HF in the cardiovascular ambulatory care setting. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from July 1, 2019, through June 30, 2023. Included for analysis were patients with HF enrolled in the National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence (PINNACLE) registry, a national ambulatory cardiovascular care quality improvement registry. Study data were analyzed from February 15, 2024, through January 15, 2025. MAIN OUTCOMES AND MEASURES: Patient-level and practice-level prescription of SGLT2i therapy. RESULTS: Of 759 915 patients (mean [SD] age, 70 [14] years; 359 270 women [47.3%]; 49 252 Black individuals [14.6%]; 278 303 White individuals [82.7%]) with HF at 191 US sites, 76 927 (10.1%) were prescribed SGLT2i. Among patients with available ejection fraction (EF) data, 20 544 (17.9%) with HF with reduced EF (HFrEF) and 36 615 (8.9%) with HF with mildly reduced EF (HFmrEF) or HF with preserved EF (HFpEF) were prescribed SGLT2i. Rates of SGLT2i use for all patients with HF increased from 4.6% in the third quarter of 2019 to 16.2% in the second quarter of 2023, from 5.1% to 28.5% for those with HFrEF, and from 4.5% to 12.8% for those with HFmrEF or HFpEF (P for trend <.001). SGLT2i was less commonly used for older persons (IQR age, 80 years vs 63 years; OR, 0.76; 95% CI, 0.75-0.77), female sex (OR, 0.79; 95% CI, 0.77-0.81), and higher systolic blood pressure (OR, 0.78; 95% CI, 0.77-0.79), whereas history of type 2 diabetes was associated with markedly higher use (OR, 3.21; 95% CI, 3.15-3.28). After adjustment for patient- and practice-level characteristics, significant variation in SGLT2i use across sites was present (90th vs 10th percentile risk practice, adjusted OR, 4.40; 95% CI, 3.76-5.52). CONCLUSIONS AND RELEVANCE: Although this study found that SGLT2i use had increased among ambulatory patients with HF during the study period, the majority of eligible patients did not receive this therapy. Older age, female sex, and higher blood pressures were associated with lower SGLT2i use with significant unexplained variation in use across practices. Systematic efforts to improve SGLT2i therapy use are warranted.
引用
- El Rafei, Gosch, Manning, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care. JAMA Cardiol. 2025. PMID: 40632519. doi:10.1001/jamacardio.2025.2145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。